事件近日，公司发布2025 年半年度中期业绩：2025 H1，和誉医药总收益为6.57亿元，同比增长20%；收入为6.12 亿元，同比增长23%；净利润为3.28亿元，同比增长59%。降本增效，提高运营效率，回购股票增强市场信心2025 H1 研发费用2.28 亿元，研发费用率为37.25%，同比减少6pct。2025H1行政开支3541.1 万元，行政费用率为5.78%，同比减少2.3pct。自...
Source Link事件近日，公司发布2025 年半年度中期业绩：2025 H1，和誉医药总收益为6.57亿元，同比增长20%；收入为6.12 亿元，同比增长23%；净利润为3.28亿元，同比增长59%。降本增效，提高运营效率，回购股票增强市场信心2025 H1 研发费用2.28 亿元，研发费用率为37.25%，同比减少6pct。2025H1行政开支3541.1 万元，行政费用率为5.78%，同比减少2.3pct。自...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.